A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention

Trial ID:
Emily Engel
To evaluate the effect of AMG 334 compared to placebo on the change from baseline in monthly migraine days

Inclusion Criteria:

  • History of at least 5 attacks of migraine without aura and/or migraine with visual sensory, speech and/or language, retinal or brainstem aura.
  • History of ≥ 15 headache days per month of which ≥ 8 headache days were assessed by the subject as migraine day.
  • Demonstrated at least 80% compliance with the eDiary .

Exclusion Criteria:

  • History of cluster headache or hemiplegic migraine headache
  • Unable to differentiate migraine from other headaches
  • Failed > 3 medication categories due to lack of efficacy for prophylactic treatment of migraine .
  • Received botulinum toxinin head or neck region within 4 months prior to screening.
  • Used a prohibited migraine prophylactic medication, device or procedure within 2 months prior to the start of the baseline phase

Contact Info:

  • Amgen Call Center
  • 866-572-6436